80 results
Page 4 of 4
8-K
EX-99.1
t3o5twl2nfa x3
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
24732y
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
d0ttd5m wdseb
15 May 20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
8:20am
8-K
EX-99.1
setnyf
6 May 20
Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
8:16am
424B2
fm41 5alcven68ce5
5 May 20
Prospectus for primary offering
4:38pm
8-K
EX-99.1
yo2ngbtktq
26 Mar 20
Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020
8:17am
8-K
EX-99.2
x4c 9m2of
6 Dec 19
Regulation FD Disclosure
4:40pm
8-K
EX-99.1
yz5 1327miov8
29 Oct 19
Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results
8:29am
8-K
EX-99.1
g3py9fc4mzz11ze bxm
9 Sep 19
Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients
7:45am
8-K
EX-99.1
rolocz3yxlxu8iqz5
12 Aug 19
Cassava Sciences Announces Second Quarter 2019 Financial Results
3:05pm
8-K
EX-99.1
67vmsqx992ie72x jf
29 Apr 19
Cassava Sciences Reports First Quarter 2019 Financial Results
8:45am